Emerging Growth Research has reiterated its Buy-Extended rating on SBC Medical Group Holdings Inc. $(SBC)$, maintaining a 12-month price target of $9.00 following the company's Q3:25 results. The research highlights SBC's stable revenue and operating profit in the quarter, a robust cash position of $127 million, and minimal long-term debt. The report points to anticipated revenue growth resuming in 2026, supported by domestic expansion and strategic M&A activities. SBC's franchise-based model delivers strong gross margins and cash conversion, positioning the company for long-term growth in the global cosmetic treatment industry.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SBC Medical Group Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276500) on December 01, 2025, and is solely responsible for the information contained therein.